| Literature DB >> 32441548 |
Mauro Toniolo1, Francesco Negri1, Marco Antonutti1, Marco Masè2, Domenico Facchin1.
Abstract
Background Northern Italy is one of the epicenters of severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) pandemic in Europe. The impact of the pandemic and the consequent lockdown on medical emergencies other than those SARS-CoV 2 pandemic related is largely unknown. The aim of this study was to analyze the epidemiologic impact of coronavirus disease 2019 pandemic on hospital admission for severe emergent cardiovascular diseases (SECDs) in a single Northern Italy large tertiary referral center. Methods and Results We quantified SECDs admissions to the Cardiology Division of Udine University Hospital between March 1, 2020 and March 31, 2020 and compared them with those of the same time frame during 2019. Compared with March 2019, we observed a significant reduction in all SECDs admissions: -30% for ST-segment-elevation acute coronary syndromes, -66% for non-ST-segment-elevation acute coronary syndromes and -50% for severe bradyarrhythmia. Conclusions A significant decrease in all SECDs admissions has been observed during the SARS-CoV 2. pandemic and was unlikely caused by a reduction in the incidence of cardiovascular diseases. Fear of contagion may have contributed to the unpredictable drop of SECDs. Social education about early recognition of symptoms of life-threatening cardiac conditions requiring appropriate care in a timely fashion may help to reduce this counterproductive phenomenon.Entities:
Keywords: COVID‐19; acute coronary syndromes; cardiology; emergent cardiovascular diseases; pacemaker
Mesh:
Year: 2020 PMID: 32441548 PMCID: PMC7670496 DOI: 10.1161/JAHA.120.017122
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Distribution of severe emergent cardiovascular diseases hospital admission per each 10‐day period of March 2020 compared with March 2019.
The upper part of the graphic shows admissions to our division for different severe emergent cardiovascular diseases in March 2019 and March 2020, divided into 10‐day blocks. The lower part of the graphic shows the difference between the total number of admissions in March 2020 compared with March 2019 for the same blocks reported above and for the whole period as well. NSTE‐ACS indicates non‐ST‐segment–elevation acute coronary syndrome; STE‐ACS, ST‐segment–elevation acute coronary syndrome.
Characteristics of Patients Admitted for Acute Coronary Syndromes During the Study Period (March 1–March 31, 2020) as Compared With Inter‐Year (March 1–March 31, 2019) Control Period
| Characteristics | Total Number of Patients (N=105) | Study Period (March 1–March 31, 2020) (N=34) | Inter‐Year Control Period (March 1–March 31, 2019) (N=71) | ||
|---|---|---|---|---|---|
| NSTE‐ACS (N=15) | STE‐ACS (N=19) | NSTE‐ACS (N=44) | STE‐ACS (N=27) | ||
| Male sex | 69 (65.7%) | 6 (40.0%) | 10 (52.6%) | 32 (72.7%) | 21 (77.8%) |
| Age, y | 67.7±11.7 | 69.7±12.9 | 61.5±12.6 | 69.0±10.1 | 69.0±11.9 |
| Age ≥65 y | 58 (55.2%) | 10 (66.6%) | 7 (36.8%) | 27 (61.3%) | 14 (51.9%) |
| Known coronary artery disease | 26 (24.8%) | 6 (40.0%) | 3 (15.8%) | 15 (34.1%) | 2 (7.4%) |
| Chronic obstructive pulmonary disease | 9 (8.6%) | 1 (6.7%) | 0 (0.0%) | 6 (13.6%) | 2 (7.4%) |
| Presentation symptom | |||||
| Angina | 61 (58.7%) | 7 (46.7%) | 14 (77.8%) | 20 (45.5%) | 20 (74.1%) |
| Dyspnea | 12 (11.5%) | 1 (6.7%) | 1 (5.5%) | 10 (22.7%) | 0 (0.0%) |
| Atypical chest pain | 23 (22.1%) | 6 (40.0%) | 1 (5.5%) | 12 (27.3%) | 4 (14.8%) |
| Major arrythmia or cardiac arrest | 8 (7.7%) | 1 (6.7%) | 2 (11.2%) | 2 (4.5%) | 3 (11.1%) |
NSTE‐ACS indicates non‐ST‐segment–elevation acute coronary syndrome; and STE‐ACS, ST‐segment–elevation acute coronary syndrome.
Characteristics of Patients Admitted for Acute Sinus Node Dysfunction or Atrioventricular Block During the Study Period (March 1–March 31, 2020) as Compared With Inter‐Year (March 1–March 31, 2019) Control Period
| Characteristics | Total Number of Patients (N=69) | Study Period (March 1–March 31, 2020) (N=23) | Inter‐Year Control Period (March 1–March 31, 2019) (N=46) |
|---|---|---|---|
| Male sex | 48 (69.6%) | 17 (73.9%) | 31 (67.4%) |
| Age, y | 78.3±13.2 | 77.9±19.2 | 78.5±9.3 |
| Age ≥65 y | 65 (94.2%) | 20 (86.9%) | 45 (97.8%) |
| Type of conduction disorder | |||
| Acute sinus node dysfunction | 16 (23.2%) | 4 (17.4%) | 12 (26.1%) |
| Second‐degree atrioventricular block | 23 (33.3%) | 10 (43.5%) | 13 (28.3%) |
| Third‐degree atrioventricular block | 30 (43.5%) | 9 (39.1%) | 21 (45.7%) |
| Presentation symptom | |||
| Syncope | 25 (36.2%) | 11 (47.8%) | 14 (30.4%) |
| Fatigue | 34 (49.3%) | 8 (34.8%) | 26 (56.5%) |
| Dizziness | 10 (14.5%) | 4 (17.4%) | 6 (13.0%) |